

**DSO Retreat**  
**May 24, 2022 in Düsseldorf**  
(Lecture Hall 13B, Building 13.55)

**Program**

09.30	Welcome	Sebastian Wesselborg (Speaker of the DSO)
09.35 h	<b>I. <u>DSO Network Program</u></b> Dissolving genetic structural variations underlying childhood malignancies using single molecule long range next generation sequencing and optical mapping techniques	Arndt Borkhardt (Pediatric Oncology, Hematology and Clinical Immunology)
09.40 h	Molecular characterization of diagnostic and predictive genomic structural variations in low-grade neuroepithelial tumors using long-read next generation sequencing and optical mapping	Nadezhda Bogodukhova (PI Guido Reifenberger, Neuropathology)
09.55 h	Identification and characterization of genomic structural variations in pediatric malignant brain tumors	Katharina Scharov (PIs Mark Remke, Pediatric Neuro-Oncogenomics/ Guido Reifenberger, Neuropathology)
10.10 h	Employing optical mapping and long-read sequencing to identify structural variations in acute lymphoblastic Leukemia predisposition and pathogenesis	Danielle Brandes (PIs Arndt, Borkhardt, Ute Fischer, Pediatric Oncology, Hematology and Clinical Immunology)
10.25 h	New algorithms for structural variant discovery in cancer genomes using optical mapping and long read data	Laura Kühle (PI Gunnar Klau, Algorithmic Bioinformatics, Computer Science)
10.40 h	Coffee Break	
11.10 h	<b>III. <u>Guests from MSSO</u></b> <sup>Aachen/Bonn/Cologne/Düsseldorf</sup>	Roland Ullrich (Speaker of the MSSO <sup>ABCD</sup> , Internal Medicine, Cologne)
11.25 h	Imaging and nanomedicine-based targeting of hypoxia-inducible factors in MPN	Julian Baumeister (Medical Clinic IV, Aachen)
11.40 h	IL17-Receptor D – underdog or promising player in modulating immune response in malignant melanoma	Anne Fröhlich (Dermatology and Allergy, Bonn)
11.55 h	Immunotherapeutic approaches in experimental cancer models	Nicole Glodde (MSSO Junior research group leader, Experimental Oncology, Bonn)
12.10 h	Immune checkpoint resistant CAR T cells in Chronic Lymphatic Leukemia (CLL)	Dario Buchholz (Internal Medicine I; Tumor Genetics and Cellular Immunotherapy, CMMC, Cologne)
12.25 h	Integration of high-throughput drug screening and molecular profiling as a precision medicine paradigm for high risk brain cancer	Nan Qin (Pediatric Oncology, Hematology and Clinical Immunology, Düsseldorf)
12.40 h	Lunch Break	
13.40 h	<b>IV. <u>DSO Network Program</u></b> Stress signaling in anticancer therapy resistance	Sebastian Wesselborg (Molecular Medicine I)
13.55 h	Identification of novel apoptosis signaling pathways for the elimination of therapy resistant tumors	Ilka Hinlage (PI Sebastian Wesselborg, Molecular Medicine I)
14.10 h	Targeting mechanisms of the DNA damage response (DDR) to increase the therapeutic efficacy of conventional anticancer therapeutics	Julia Mann (PI Gerhard Fritz, Toxicology)
14.25 h	Targeting the autophagy-initiating class III PtdIns3K complex for cancer therapy	Yadong Sun (PI Björn Stork, Molecular Medicine I)
14.40 h	Targeting heat shock proteins in therapy resistant BCP-ALL	Melina Vogt (PIs Sanil Bhatia, Pediatric Oncol., Hematol. & Clinical Immunol./ Holger Gohlke, Thomas Kurz, Pharmaceutical a. Medicinal Chemistry)
14.55 h	Coffee Break	
15.30 h	<b>V. <u>Invited guest lecture</u></b> Modelling Antibody Drug Conjugate Responses in Bladder Cancer	Michael Hölzel (Experimentelle Onkologie; Bonn)
16.15 h	Closing remarks	Sebastian Wesselborg

Time/Location Mai 24, 2022, 9.30 – 17.00 h, Building 13.55, Lecture Hall 13B

Steering board Irene Esposito, Tanja Fehm, Norbert Gattermann, Bernhard Homey, Tom Lüdde, Daniel Nettersheim, Guido Reifenberger, Sebastian Wesselborg

Organisation Cornelia Höner

**Address** Heinrich-Heine-Universität Düsseldorf  
Düsseldorf School of Oncology (DSO)  
Universitätsstr. 1, Geb. 22.07.U1  
40225 Düsseldorf

**Registration** <http://www.hhu.de/dso>